HRP20030870B1 - Aripiprazole oral solution - Google Patents

Aripiprazole oral solution

Info

Publication number: HRP20030870B1
Authority: HR; Croatia
Prior art keywords: acid; oral solution; aripiprazole; solution; aripiprazole oral
Prior art date: 2001-04-25

Application number

HR20030870A

Other languages

English (en)

Croatian (hr)

Inventor

Parab Prakash

Chou Joyce

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-25

Filing date

2003-10-24

Publication date

2011-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23099862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20030870(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-10-24 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2004-06-30 Publication of HRP20030870A2 publication Critical patent/HRP20030870A2/hr

2011-10-31 Publication of HRP20030870B1 publication Critical patent/HRP20030870B1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Psychiatry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

HR20030870A 2001-04-25 2003-10-24 Aripiprazole oral solution HRP20030870B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28671801P	2001-04-25	2001-04-25
PCT/US2002/013048 WO2002085366A1 (en)	2001-04-25	2002-04-24	Aripiprazole oral solution

Publications (2)

Publication Number	Publication Date
HRP20030870A2 HRP20030870A2 (en)	2004-06-30
HRP20030870B1 true HRP20030870B1 (en)	2011-10-31

Family

ID=23099862

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20030870A HRP20030870B1 (en)	2001-04-25	2003-10-24	Aripiprazole oral solution

Country Status (37)

Country	Link
US (1)	US6977257B2 (sh)
EP (2)	EP2436384B2 (sh)
JP (1)	JP4401077B2 (sh)
KR (1)	KR100909329B1 (sh)
CN (1)	CN1512884B (sh)
AR (1)	AR033168A1 (sh)
AT (1)	ATE537831T1 (sh)
AU (1)	AU2002254722B2 (sh)
BG (1)	BG66177B1 (sh)
BR (1)	BR0208986A (sh)
CA (1)	CA2445276C (sh)
CY (1)	CY1112606T1 (sh)
CZ (1)	CZ306181B6 (sh)
DK (1)	DK1381367T3 (sh)
EE (1)	EE05581B1 (sh)
ES (1)	ES2377855T3 (sh)
GE (1)	GEP20053602B (sh)
HK (2)	HK1058316A1 (sh)
HR (1)	HRP20030870B1 (sh)
HU (1)	HU230456B1 (sh)
IL (2)	IL158202A0 (sh)
IS (1)	IS2863B (sh)
MX (1)	MXPA03009728A (sh)
MY (1)	MY129350A (sh)
NO (1)	NO324606B1 (sh)
NZ (1)	NZ528550A (sh)
PE (1)	PE20021086A1 (sh)
PL (1)	PL206882B1 (sh)
PT (1)	PT1381367E (sh)
RS (1)	RS52082B (sh)
RU (1)	RU2295960C2 (sh)
SK (1)	SK287948B6 (sh)
TW (1)	TWI337865B (sh)
UA (1)	UA76144C2 (sh)
UY (1)	UY27273A1 (sh)
WO (1)	WO2002085366A1 (sh)
ZA (1)	ZA200307797B (sh)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6770478B2 (en) *	2000-02-10	2004-08-03	The Regents Of The University Of California	Erythrocytic cells and method for preserving cells
GEP20063996B (en) *	2002-08-20	2006-12-11	Bristol Myers Squibb Co	Aripiprazole complex formulation and use thereof
CN1867359B (zh) *	2003-10-08	2010-12-15	马林克罗特公司	哌甲酯溶液及其制药用途和制备方法
PL1675573T4 (pl)	2003-10-23	2016-04-29	Otsuka Pharma Co Ltd	Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
CA2552988A1 (en) *	2004-01-21	2005-08-04	Janssen Pharmaceutica Nv	Mitratapide oral solution
EP1933814A2 (en)	2005-09-15	2008-06-25	Elan Pharma International Limited	Nanoparticulate aripiprazole formulations
PL1808165T3 (pl) *	2006-01-05	2009-09-30	Teva Pharma	Suche formulacje aripiprazolu
DE602006004694D1 (de) *	2006-01-05	2009-02-26	Teva Pharma	Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen
JP4892264B2 (ja) *	2006-03-30	2012-03-07	高田製薬株式会社	リスペリドン水性液剤
WO2007144874A1 (en)	2006-06-12	2007-12-21	Hadasit Medical Research Services And Development Ltd.	Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
GB0618879D0 (en)	2006-09-26	2006-11-01	Zysis Ltd	Pharmaceutical compositions
PL2170279T3 (pl)	2007-07-31	2018-05-30	Otsuka Pharmaceutical Co., Ltd.	Sposoby wytwarzania zawiesiny arypiprazolu i liofilizowanej formulacji
WO2009042166A1 (en) *	2007-09-25	2009-04-02	Panacos Pharmaceuticals, Inc.	Liquid bevirimat dosage forms for oral administration
GB2456183A (en) *	2008-01-04	2009-07-08	Gw Pharma Ltd	Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
MX2011006891A (es)	2008-12-23	2011-10-06	Pharmasset Inc	Fosforamidatos de nucleosidos.
PA8855801A1 (es)	2008-12-23	2010-07-27		Sintesis de nucleosidos de purina
KR20110098849A (ko)	2008-12-23	2011-09-01	파마셋 인코포레이티드	뉴클레오시드 유사체
TWI598358B (zh)	2009-05-20	2017-09-11	基利法瑪席特有限責任公司	核苷磷醯胺
WO2010146872A1 (ja) *	2009-06-19	2010-12-23	株式会社メドレックス	アリピプラゾールと有機酸を有効成分とする外用剤組成物
TR201000948A1 (tr)	2010-02-09	2011-08-22	Sanovel İlaç San.Ve Ti̇c.A.Ş.	Aripiprazol formülasyonları.
US8563530B2 (en)	2010-03-31	2013-10-22	Gilead Pharmassel LLC	Purine nucleoside phosphoramidate
UY33312A (es)	2010-03-31	2011-10-31	Pharmasset Inc	Fosforamidato de nucleosido de purina
UY33311A (es)	2010-03-31	2011-10-31	Pharmasset Inc	Fosforamidatos de nucleosidos
WO2012075140A1 (en)	2010-11-30	2012-06-07	Pharmasset, Inc.	Compounds
PL3156056T3 (pl)	2011-03-18	2024-04-29	Alkermes Pharma Ireland Limited	Kompozycje farmaceutyczne zawierające estry sorbitanu
JO3410B1 (ar) *	2011-06-07	2019-10-20	Otsuka Pharma Co Ltd	تركيبة أريبيبرازول مجفف بالتبريد
JP6034377B2 (ja) *	2011-06-27	2016-11-30	シャンハイチョンシファーマシューティカルコーポレイション	アリピプラゾール医薬製剤及びその調製方法
CN102846616B (zh) *	2011-06-27	2015-05-06	上海中西制药有限公司	一种阿立哌唑制剂及其制备方法
AR088372A1 (es) *	2011-10-19	2014-05-28	Otsuka Pharma Co Ltd	Solucion para administracion oral
ES2764383T3 (es)	2012-03-19	2020-06-03	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que comprenden ésteres de glicerol
ES2765036T3 (es)	2012-03-19	2020-06-05	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que comprenden esteres de ácidos grasos
NZ630428A (en)	2012-03-19	2017-02-24	Alkermes Pharma Ireland Ltd	Pharmaceutical compositions comprising benzyl alcohol
JOP20200109A1 (ar)	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن
WO2014002553A1 (ja)	2012-06-29	2014-01-03	丸石製薬株式会社	アリピプラゾールの経口医薬製剤
JP5341282B1 (ja) *	2012-06-29	2013-11-13	丸石製薬株式会社	アリピプラゾールの経口医薬製剤
KR101571670B1 (ko) *	2012-08-08	2015-11-25	주식회사 씨엠지제약	아리피프라졸을 포함하는 경구용 속용 필름 제제
ES2792149T3 (es)	2012-09-19	2020-11-10	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
WO2014052678A1 (en) *	2012-09-26	2014-04-03	Bristol-Myers Squibb Company	Apixaban liquid formulations
US8568747B1 (en)	2012-10-05	2013-10-29	Silvergate Pharmaceuticals, Inc.	Enalapril compositions
US20140107130A1 (en) *	2012-10-11	2014-04-17	Antrim Pharmaceuticals, LLC	Oral Solution Formulations of Aripiprazole
EP2908859B1 (en)	2012-10-16	2017-05-17	Arven Ilac Sanayi ve Ticaret A.S.	Aripiprazole formulations
EP3610890A1 (en)	2012-11-14	2020-02-19	The Johns Hopkins University	Methods and compositions for treating schizophrenia
JP6203682B2 (ja) *	2013-07-10	2017-09-27	共和薬品工業株式会社	アリピプラゾール含有水性液剤
CN103393594A (zh) *	2013-08-22	2013-11-20	万特制药(海南)有限公司	一种新的阿立哌唑的制剂组合物
MA39495A (fr)	2014-03-20	2015-09-24	Alkermes Pharma Ireland Ltd	Formulations d'aripiprazole présentant des vitesses d'injection plus élevées
WO2016189504A1 (en) *	2015-05-28	2016-12-01	Leiutis Pharmaceuticals Pvt Ltd	Non-lyophilized compositions of aripiprazole and methods of preparation thereof
JP6039849B1 (ja) *	2015-06-12	2016-12-07	高田製薬株式会社	アリピプラゾール含有内用液剤
WO2017025930A1 (en) *	2015-08-12	2017-02-16	Ftf Pharma Private Limited	Oral solution of aripiprazole
US9463183B1 (en)	2015-10-30	2016-10-11	Silvergate Pharmaceuticals, Inc.	Lisinopril formulations
US9669008B1 (en)	2016-03-18	2017-06-06	Silvergate Pharmaceuticals, Inc.	Enalapril formulations
CN108434146A (zh) *	2017-02-16	2018-08-24	天津国际生物医药联合研究院	一种hiv-1整合酶抑制剂的溶液剂及其制备方法和应用
CN109498556A (zh) *	2017-09-15	2019-03-22	万特制药(海南)有限公司	阿立哌唑口服溶液及其制备方法
CN112423754A (zh)	2018-03-05	2021-02-26	奥克梅斯制药爱尔兰有限公司	阿立哌唑的给药策略
CN112666267B (zh) *	2019-10-15	2023-09-26	上海上药中西制药有限公司	一种阿立哌唑药品有关物质的检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5006528A (en) *	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU843739A3 (ru) †	1978-02-17	1981-06-30	Карл Томэ Гмбх (Фирма)	Способ получени карбостириловыхили ОКСиНдОлОВыХ пРОизВОдНыХ
JPS54130587A (en)	1978-03-30	1979-10-09	Otsuka Pharmaceut Co Ltd	Carbostyryl derivative
PH17194A (en)	1980-03-06	1984-06-19	Otsuka Pharma Co Ltd	Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS5959663A (ja) †	1982-09-29	1984-04-05	Otsuka Pharmaceut Co Ltd	カルボスチリル誘導体−シクロデキストリン包接化合物
JP3265680B2 (ja) *	1992-03-12	2002-03-11	大正製薬株式会社	経口製剤用組成物
US5457099A (en) †	1992-07-02	1995-10-10	Sawai Pharmaceutical Co., Ltd.	Carbostyril derivatives and antiallergic agent
TW254855B (sh)	1993-07-28	1995-08-21	Otsuka Pharma Co Ltd
JP2001518879A (ja) *	1997-03-31	2001-10-16	ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド	薬剤化合物の向上した浸透性のための溶媒システム
US20030077227A1 (en) *	1997-10-01	2003-04-24	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
BR9913432A (pt) *	1998-09-03	2001-10-09	Alcide Corp	Germicidas tópicos resistentes ao congelamento e métodos a eles relacionados
US20020076437A1 (en) *	2000-04-12	2002-06-20	Sanjeev Kothari	Flashmelt oral dosage formulation
CA2311734C (en) *	2000-04-12	2011-03-08	Bristol-Myers Squibb Company	Flash-melt oral dosage formulation

2002
- 2002-03-28 MY MYPI20021124A patent/MY129350A/en unknown
- 2002-04-15 AR ARP020101366A patent/AR033168A1/es unknown
- 2002-04-19 TW TW091108139A patent/TWI337865B/zh not_active IP Right Cessation
- 2002-04-24 CZ CZ2003-2821A patent/CZ306181B6/cs not_active IP Right Cessation
- 2002-04-24 AT AT02723964T patent/ATE537831T1/de active
- 2002-04-24 RU RU2003132426/15A patent/RU2295960C2/ru not_active IP Right Cessation
- 2002-04-24 EP EP11190103.9A patent/EP2436384B2/en not_active Expired - Lifetime
- 2002-04-24 CN CN028112148A patent/CN1512884B/zh not_active Ceased
- 2002-04-24 MX MXPA03009728A patent/MXPA03009728A/es active IP Right Grant
- 2002-04-24 EP EP02723964A patent/EP1381367B1/en not_active Expired - Lifetime
- 2002-04-24 UY UY27273A patent/UY27273A1/es not_active Application Discontinuation
- 2002-04-24 HU HU0303946A patent/HU230456B1/hu not_active IP Right Cessation
- 2002-04-24 BR BR0208986-6A patent/BR0208986A/pt active Search and Examination
- 2002-04-24 SK SK1264-2003A patent/SK287948B6/sk not_active IP Right Cessation
- 2002-04-24 US US10/131,304 patent/US6977257B2/en not_active Expired - Lifetime
- 2002-04-24 PL PL364666A patent/PL206882B1/pl unknown
- 2002-04-24 RS YU84703A patent/RS52082B/sr unknown
- 2002-04-24 GE GE5332A patent/GEP20053602B/en unknown
- 2002-04-24 AU AU2002254722A patent/AU2002254722B2/en not_active Expired
- 2002-04-24 DK DK02723964.9T patent/DK1381367T3/da active
- 2002-04-24 WO PCT/US2002/013048 patent/WO2002085366A1/en active IP Right Grant
- 2002-04-24 PT PT02723964T patent/PT1381367E/pt unknown
- 2002-04-24 EE EEP200300523A patent/EE05581B1/xx not_active IP Right Cessation
- 2002-04-24 UA UA20031110599A patent/UA76144C2/uk unknown
- 2002-04-24 ES ES02723964T patent/ES2377855T3/es not_active Expired - Lifetime
- 2002-04-24 NZ NZ528550A patent/NZ528550A/en not_active IP Right Cessation
- 2002-04-24 KR KR1020037013943A patent/KR100909329B1/ko active IP Right Grant
- 2002-04-24 JP JP2002582939A patent/JP4401077B2/ja not_active Expired - Lifetime
- 2002-04-24 CA CA002445276A patent/CA2445276C/en not_active Expired - Fee Related
- 2002-04-24 IL IL15820202A patent/IL158202A0/xx active IP Right Grant
- 2002-04-25 PE PE2002000346A patent/PE20021086A1/es not_active Application Discontinuation
2003
- 2003-10-01 IL IL158202A patent/IL158202A/en not_active IP Right Cessation
- 2003-10-01 BG BG108216A patent/BG66177B1/bg unknown
- 2003-10-06 ZA ZA200307797A patent/ZA200307797B/en unknown
- 2003-10-14 IS IS6994A patent/IS2863B/is unknown
- 2003-10-21 NO NO20034705A patent/NO324606B1/no not_active IP Right Cessation
- 2003-10-24 HR HR20030870A patent/HRP20030870B1/xx not_active IP Right Cessation
2004
- 2004-02-19 HK HK04101190.2A patent/HK1058316A1/xx not_active IP Right Cessation
2012
- 2012-03-14 CY CY20121100273T patent/CY1112606T1/el unknown
- 2012-09-28 HK HK12109608.1A patent/HK1168792A1/xx not_active IP Right Cessation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5006528A (en) *	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives

Also Published As

Publication number	Publication date
DK1381367T3 (da)	2012-04-10
EP2436384B1 (en)	2015-06-10
SK12642003A3 (sk)	2004-07-07
EP2436384A3 (en)	2012-09-19
CZ20032821A3 (cs)	2004-09-15
IS6994A (is)	2003-10-14
GEP20053602B (en)	2005-08-10
RU2003132426A (ru)	2005-04-20
BG108216A (bg)	2004-12-30
NO20034705L (no)	2003-11-28
NO20034705D0 (no)	2003-10-21
EP1381367B1 (en)	2011-12-21
NZ528550A (en)	2005-03-24
HUP0303946A3 (en)	2005-06-28
EP1381367A1 (en)	2004-01-21
HK1168792A1 (en)	2013-01-11
CY1112606T1 (el)	2016-02-10
KR20030096332A (ko)	2003-12-24
SK287948B6 (sk)	2012-06-04
HK1058316A1 (en)	2004-05-14
CA2445276A1 (en)	2002-10-31
EE05581B1 (et)	2012-10-15
JP2004532225A (ja)	2004-10-21
HU230456B1 (hu)	2016-07-28
TWI337865B (en)	2011-03-01
EE200300523A (et)	2004-02-16
CN1512884B (zh)	2010-05-26
US20020193438A1 (en)	2002-12-19
MXPA03009728A (es)	2004-01-29
IS2863B (is)	2013-12-15
ATE537831T1 (de)	2012-01-15
AR033168A1 (es)	2003-12-03
IL158202A (en)	2008-04-13
MY129350A (en)	2007-03-30
JP4401077B2 (ja)	2010-01-20
UY27273A1 (es)	2002-11-29
UA76144C2 (uk)	2006-07-17
KR100909329B1 (ko)	2009-07-24
HUP0303946A2 (hu)	2004-04-28
CZ306181B6 (cs)	2016-09-14
BG66177B1 (bg)	2011-11-30
ZA200307797B (en)	2004-10-06
CN1512884A (zh)	2004-07-14
PE20021086A1 (es)	2002-12-14
PL364666A1 (en)	2004-12-13
PT1381367E (pt)	2012-03-01
PL206882B1 (pl)	2010-10-29
EP2436384B2 (en)	2018-05-23
US6977257B2 (en)	2005-12-20
RU2295960C2 (ru)	2007-03-27
WO2002085366A1 (en)	2002-10-31
EP1381367A4 (en)	2009-07-01
CA2445276C (en)	2009-10-13
EP2436384A2 (en)	2012-04-04
HRP20030870A2 (en)	2004-06-30
IL158202A0 (en)	2004-05-12
BR0208986A (pt)	2004-04-20
NO324606B1 (no)	2007-11-26
RS52082B (sr)	2012-06-30
YU84703A (sh)	2006-08-17
ES2377855T3 (es)	2012-04-02
AU2002254722B2 (en)	2006-11-09

Publication	Publication Date	Title
HRP20030870B1 (en)	2011-10-31	Aripiprazole oral solution
RS50360B (sr)	2009-11-10	Farmaceutske formulacije derivata platine
HRP20010332B1 (en)	2011-01-31	Pharmaceutical moxifloxacin preparation
DZ2964A1 (fr)	2004-03-15	Diphénylurées substituées nouvelles, et compositions pharmaceutiques les contenant.
MX9600857A (es)	1997-06-28	Forma de dosificacion i en tabletas, con unidades multiples.
WO2005045689A8 (en)	2007-06-28	Methods and systems for network coordination
HRP20020198B1 (en)	2011-02-28	Moxifloxacin formulation containing common salt
ATE310526T1 (de)	2005-12-15	Stabiler extrakt aus hypericum perforatum l., verfahren zu seiner herstellung und pharmazeutische zubereitungen
RS51737B (sr)	2011-10-31	Korišćenje inhibitora il-18
ATE304013T1 (de)	2005-09-15	1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ME00578A (en)	2011-12-20	Use of gastrointestinal lipase inhibitors
HRP20030050B1 (en)	2011-07-31	Sustained-release preparations of quinolone antibiotics and method for preparation thereof
IS6956A (is)	2003-09-15	Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því
RS49599B (sr)	2007-06-04	Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
DK1104289T3 (da)	2006-05-15	Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
HRP20010878B1 (en)	2007-03-31	Ziprasidone suspension
NO20026212L (no)	2003-02-06	Forbindelse for medikamentavleveringssystem og fremgangsmåte for fremstilling av forbindelsen
TW200420557A (en)	2004-10-16	Salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and anti-bacterially pharmaceutical composition comprising the same as active ingredient
DE60131085D1 (de)	2007-12-06	Antimikrobielle sulfonamide-derivate von lipopeptidantibiotika
DE69711633D1 (de)	2002-05-08	Stabile derivate von ubiquinol, verfahren zu ihrer herstellung und ihre pharmazeutische anwendung
TR199903065T2 (xx)	2000-09-21	Oral uygulamaya y�nelik rapamisin form�lasyonlar�.
HRP20000703B1 (en)	2009-11-30	Stabile compositions levosimendan and alginic acid
DE69011046D1 (de)	1994-09-01	Pyridinderivate, Verfahren zur Herstellung und pharmazeutische Zusammensetzungen.
ATE267194T1 (de)	2004-06-15	Medikamente geeignet zur behandlung von proliferativen erkrankungen
DE60029979D1 (de)	2006-09-21	LIPOSOMZUSAMMENSETZUNG VON 6,9-BIS-i(2-AMINOETHYL)-AMINOöBENZOiGöISOQUINOLIN-5,10-DIONE-DIMALEAT

Legal Events

Date	Code	Title	Description
2004-06-30	A1OB	Publication of a patent application
2004-12-20	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2011-10-31	B1PR	Patent granted
2014-06-11	PNAN	Change of the applicant name, address/residence	Owner name: BRISTOL-MYERS SQUIBB COMPANY, US
2014-06-11	PPPP	Transfer of rights	Owner name: OTSUKA PHARMACEUTICAL CO., LTD., JP
2018-04-10	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20180410 Year of fee payment: 17
2019-11-05	PBON	Lapse due to non-payment of renewal fee	Effective date: 20190424